A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis

NCT03260595 | Completed Phase 1 Results

• 1 other identifier: C3291029
• Study Type: interventional
• Target: 32
• Locations: 1 country
• Sites: 1

Brief Summary

This is a Phase 1 parallel-cohort study of crisaborole ointment 2% to evaluate the skin irritation potential in adult Japanese healthy subjects in Cohort 1, and to evaluate the safety, tolerability and PK in adult Japanese subjects with mild to moderate AD in Cohort 2.

Conditions

Healthy; Atopic Dermatitis

Outcome Measures

Primary Outcomes (5)

• Cohort 1: Skin Irritation Index

  The skin irritation index is a common measure of skin irritation potential (safety criteria) of investigational product and derived using skin irritation scores. Individual skin irritation score ranges from 0-4, where 0 = no reaction, 0.5 = mild erythema, 1 = erythema, 2 = erythema with edema and papula, 3 = erythema with edema, papula and small water blister, 4 = large water blister, higher score indicates more skin irritation. For each investigational product, the skin irritation index was calculated as the sum of the maximum individual skin irritation scores divided by the number of evaluable participants and multiplied by 100, which ranged from 0 to 400; where, lower score indicated less skin irritation and higher score indicated more skin irritation.

  Day 3 to 4

• Cohort 2: Number of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs)

  An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 28 days after last dose of study drug (up to Day 36) that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-serious AEs.

  Baseline up to Day 36

• Cohort 2: Number of Participants With Clinically Significant Vital Signs Abnormalities

  Vital signs included pulse rate and blood pressure. Clinical significance of vital signs was determined at the investigator's discretion.

  Baseline up to end of treatment (Day 8)

• Cohort 2: Number of Participants With Laboratory Tests Abnormalities

  Laboratory tests abnormalities included: hematology (haemoglobin\[Hb\], haematocrit and erythrocytes\<0.8\*lower limit of normal\[LLN\]; erythrocyte mean corpuscular volume, erythrocyte mean corpuscular Hb and erythrocyte mean corpuscular Hb concentration \<0.9\*LLN and \>1.1\*upper limit of normal\[ULN\]; platelets \<0.5\*LLN and \>1.75\*ULN; leukocytes \<0.6\*LLN and \>1.5\*ULN; lymphocytes/leukocytes\[%\], neutrophils/leukocytes\[%\] \<0.8\*LLN and \>1.2\*ULN; basophils/leukocytes\[%\], eosinophils/leukocytes\[%\], monocytes/leukocytes\[% \]\>1.2\*ULN); clinical chemistry(bilirubin\>1.5\*ULN; aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase\>3.0\*ULN; protein and albumin\<0.8\*LLN and \>1.2\*ULN; urea nitrogen and creatinine \>1.3\*ULN; urate\>1.2\*ULN; sodium \<0.95\*LLN and \>1.05\*ULN; potassium, chloride and calcium \<0.9\*LLN and \>1.1\*ULN; fasting glucose \<0.6\*LLN and \>1.5\*ULN); and urinalysis (pH \<4.5 and \>8; glucose, ketones, protein, Hb, urobilinogen, bilirubin, nitrite and leukocyte esterase \>=1).

  Baseline up to end of treatment (Day 8)

• Cohort 2: Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities

  Criteria for clinically significant ECG abnormalities included: QT interval \>=500 milliseconds (msec); QT interval corrected using the Fridericia's formula (QTcF) \>=450 msec to \<480 msec, \>=480 msec and \>=500 msec; increase from baseline in QTcF interval \>=30 msec to \<60 msec and \>=60 msec.

  Baseline up to end of treatment (Day 8)

Secondary Outcomes (8)

• Cohort 1: Number of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs)

  Baseline up to Day 29

• Cohort 2: Maximum Observed Plasma Concentration (Cmax) of Crisaborole and Its Identified Main Oxidative Metabolites

  Pre-dose, 3, 12 and 24 hours post-dose on Day 1 and Day 8

• Cohort 2: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crisaborole and Its Metabolites

  Pre-dose, 3, 12 and 24 hours post-dose on Day 1 and Day 8

• Cohort 2: Area Under the Plasma Concentration-Time Curve From Time Zero Until the Last Measurable Concentration (AUClast) of Crisaborole and Its Identified Main Oxidative Metabolites

  Pre-dose, 3, 12 and 24 hours post-dose on Day 1 and Day 8

• Cohort 2: Area Under the Plasma Concentration-Time Curve From Time Zero to the 24 Hours Post-Dose (AUC24) of Crisaborole and Its Identified Main Oxidative Metabolites (AN7602 and AN8323)

  Pre-dose, 3, 12 and 24 hours post-dose on Day 1 and Day 8

Study Arms (2)

Crisaborole ointment 2%

EXPERIMENTAL

Drug: Crisaborole ointment 2%

Vehicle

PLACEBO COMPARATOR

Drug: Vehicle

Interventions

Crisaborole ointment 2% DRUG

Crisaborole ointment 2%

Crisaborole ointment 2%

Vehicle DRUG

Vehicle

Vehicle

Eligibility Criteria

• Age: 20 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Cohort 1
• Healthy male Japanese subjects who, at the time of screening, are between the ages of 20 and 55 years, inclusive.
• Healthy skin on which reddening can be easily recognized in the area of the test fields.
• Cohort 2
• Male or female Japanese subjects aged 20 years to 55 years (inclusive) at the time of screening, and in generally good health except for AD.
• Diagnosis of AD based on the criteria of Hanifin and Rajka (1980).
• Has at least 25% Treatable %BSA on Day 1 (excluding the scalp and designated venous access areas).
• Has an Investigator's static global assessment (ISGA) score of Mild (2) or Moderate (3) on Day 1.

You may not qualify if:

• Cohort 1
• Subjects who have any visible skin disease at the application site which, in the opinion of the investigative personnel, will interfere with the evaluation of the test site reaction.
• Subjects who have psoriasis and/or active AD/eczema.
• Subjects who have a history of AD.
• Subjects who have damaged skin in or around the test sites, including sunburn, excessively deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other disfigurations of the test site.
• Known sensitivity to any of the components of the investigational products.
• History of the rash to the adhesive plaster, contact dermatitis to metal, or cosmetic and household articles.
• Cohort 2
• Has any clinically significant medical disorder, condition, disease (including active or potentially recurrent dermatological conditions other than AD), significant physical examination or laboratory findings that may interfere with study objectives, in the Investigator's opinion.
• Has unstable AD or a consistent requirement for strong to strongest potency topical corticosteroids to manage AD signs and symptoms.
• Has a significant active systemic or localized infection, including known actively infected AD.
• Has a history or evidence of clinically significant or severe allergies (eg, seasonal, pet dander, environmental, food) requiring acute or chronic treatment.
• Has recent or anticipated concomitant use of topical or systemic therapies that might alter the course of AD.
• Has a history of recent (within 4 weeks of Day 1) sunbathing, tanning bed use, or ultraviolet (UV) light B therapy (UVB) or psoralen plus UVA \[PUVA\]).
• Has a known sensitivity to any of the components of crisaborole ointment 2%.

Sponsors & Collaborators

• Pfizer: lead

Study Sites (1)

Medical Corporation Heishinkai OPHAC Hospital

Osaka, Osaka, 532-0003, Japan

Location

Related Links

• To obtain contact information for a study center near you, click here.

MeSH Terms

Conditions

Dermatitis, Atopic

Condition Hierarchy (Ancestors)

Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Dermatitis; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Results Point of Contact

• Title: Pfizer ClinicalTrials.gov Call Center
• Organization: Pfizer, Inc.

ClinicalTrials.gov_Inquiries@pfizer.com

1-800-718-1021

Study Officials

• Pfizer CT.gov Call Center

  Pfizer

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 9, 2017
• First Posted: August 24, 2017
• Study Start: September 13, 2017
• Primary Completion: November 27, 2017
• Study Completion: November 27, 2017
• Last Updated: March 1, 2019
• Results First Posted: March 1, 2019

Record last verified: 2018-10

Data Sharing

• IPD Sharing: Will not share

Locations

JP (1)